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We propose a straightforward method to estimate the purity of vesicle preparations by comparing the ratio of
nano-vesicle counts to protein concentration, using tools such as the increasingly available NanoSight
platform and a colorimetric protein assay such as the BCA-assay. Such an approach is simple enough to apply
to every vesicle preparation within a given laboratory, assisting researchers as a routine quality control step.
Also, the approach may aid in comparing/standardising vesicle purity across diverse studies, and may be
of particular importance in evaluating vesicular biomarkers. We herein propose some criteria to aid in the
definition of pure vesicles.
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V
arious biological fluids have been shown to
contain extracellular vesicles. The utility of
extracellular vesicles as disease biomarkers has
attracted considerable interest in recent years (1). Studies
to evaluate the physiological role(s) of extracellular
vesicles also continue to rapidly advance the field (2),
and recently their manipulation as therapeutic agents is
now being vigorously investigated (3). However, there is a
fairly fundamental issue in these research areas that is
not satisfactorily addressed, i.e. how pure are the vesicle
preparations being analysed.
Most researchers utilise ultracentrifugation-based pro-
tocols for vesicle purifications (4), but this approach can
co-isolate a complex assortment of non-vesicular mate-
rials. This is a particular problem with challenging
source material such as serum, urine or cancer-related
effusions, estimating the purity of samples remains dif-
ficult, with inconsistent approaches across diverse
studies.
Knowing something about purity is of critical im-
portance to demonstrate, for example, that a given
biomarker or functional property is associated with
vesicles and not with co-isolated contaminants. There
are several current approaches that attempt to address
this. First, examination of samples by electron micro-
scopy can be informative, giving an indication of
vesicular morphology and revealing the presence of larger
non-vesicular particulates. However, this approach can-
not measure the amount of soluble factors contaminating
the sample. It is also a method that is unsuited to routine
daily use, as not every research group has ready access
to EM.
Another approach is to look specifically for proteins
that would not be expected in a vesicle preparation.
Western blotting for markers such as calnexin or gp96
is commonly utilised for this purpose. Whilst this
approach can be informative, it is not quantitative, and
the selection of these ‘‘exclusion markers’’ is difficult. For
example, some complement components (5) or IgG (6)
may be genuinely associated with some exosomes and
assuming their presence within vesicles preparations as
contaminants may not be strictly accurate. Furthermore,
our incomplete understanding of how proteins are loaded
into vesicles, and how strictly controlled this may be
under varying situations such as in disease, compounds
this approach significantly.
Being able to estimate and compare sample purity, in a
general, simple and quantitative manner will be immen-
sely useful. Be it from an intra-group perspective as a
general tool to monitor the quality of preparations, or
more broadly as an approach to aid in establishing some
international standardisation in the field as to what is
an acceptably pure vesicular sample. This aspect will be
of particular relevance with the advent of exosome
therapeutics in humans.
Here, we present an approach that appears to serve this
requirement well, based simply on measuring the particle
to protein ratio.
Methods
Source of exosomes
Cancer cell lines were maintained at high cell density in
Integra bioreactor flasks (7) or, where stated, in standard
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2D 75 cm2 flasks. Cell lines included DU145, LNCAP,
PC3 (prostate cancer), HT1376 (bladder cancer) and
MCF7 (breast cancer), all from ATCC, Teddington, UK.
We also used a mesothelioma cell line, developed in the
department from pleural fluid specimens (we term #15).
Cells were maintained in RPMI1640, with L-glutamine
and antibiotics, and 10% FBS (Lonza). The FBS was
depleted of vesicles by overnight ultracentrifugation at
100,000 g, followed by filtration through 0.22 and then
0.1-mm vacuum-driven filter (Millipore). As a source of
ex vivo exosomes, we collected fresh urine from three
healthy male volunteers and fresh serum from three
healthy donors.
Exosome isolation
Exosomes were purified from cell-conditioned media
(1015 ml) or biological fluids (urine10 ml; serum
B2 ml), using a basic differential ultracentrifugation
method (400 g, 5 min, 2,000 g, 15 min, 10,000 g, 40
min), followed by centrifugation at 100,000 g for 60 min.
For some isolations, this final pellet was subjected to
a single wash step by re-suspending in 5 ml PBS and
centrifuging again at 100,000 g, 60 min (Optima-MAX
ultracentrifuge, with TLA110 rotor and Optiseal tubes,
Beckman coulter). For cells cultured in bioreactor flasks,
we employed our usual exosome isolation method,
involving pre-clearing centrifugations as above, but sub-
stituting the first pelleting step with centrifugation on a
30% sucrose/D2O cushion for 60 min. The collected
cushion was subjected to one wash in PBS (8). For urine
and serum samples, specimens were subjected to the
same pre-clearing steps, but the pelleting speed used was
120,000 g.
Protein assay
An aliquot of each preparation was kept for protein
estimation using the micro-BCA kit from Thermo Scien-
tific Pierce (Thermo Fisher Scientific, Northumberland,
UK). Exosome preparations, usually diluted 1 in 8 to 1 in
20, were compared in triplicates against serially diluted
BSA as standard. Values were extrapolated from this
curve, using a third-order polynomial equation, with
r20.98 for each assay.
Nanoparticle tracking analysis (NanoSightTM)
Vesicles present in purified or unpurified samples were
analysed by nanoparticle tracking, using the NanoSight
LM10 system (NanoSight Ltd, Amesbury, UK), config-
ured with a 405 nm laser and a high sensitivity digital
camera system (OrcaFlash2.8, Hamamatsu C11440,
NanoSight Ltd). Videos were collected and analysed
using the NTA-software (version 2.3), with the minimal
expected particle size, minimum track length, and blur
setting, all set to automatic. Camera shutter speed was
fixed at 30.01 ms and camera gain was set to 500. Camera
sensitivity and detection threshold were set close to
maximum (15 or 16) and minimum (3 or 4), respectively,
to reveal small particles. Ambient temperature was
recorded manually, ranging from 24 to 278C. Each
sample was diluted in nanoparticle-free water (Fresenius
Kabi, Runcorn, UK), so that the concentration was
between 2108 and 9108 particles/ml. Samples were
administered and recorded under controlled flow, using
the NanoSight syringe pump and script control system,
and for each sample, six videos of 3060 seconds
duration were recorded, with a 10-second delay between
recordings, generating six replicate histograms that were
averaged. Therefore, the typical number of completed
tracks per sample was approximately 1,200. The area
under the curve was calculated using Prism-4 software
version 4.03 (Graph Pad, San Diego, CA), to give average
particle counts from these replicates.
Statistical analysis
Graphs and statistical analyses were performed using
Prism-4 software (version 4.03, Graph Pad, San Diego,
CA). In all experiments, one-way ANOVA, with Tukey’s
post-test was used. Differences with p values of 0.05 or
less are considered significant *pB0.05, **pB0.001,
***pB0.0001.
Results
Particle counting by NanoSight
As an example of nanoparticle analysis, we present
typical analyses of standard nano-beads (of 100 nm
size), measured under fluid flow six times (Fig. 1A).
Each individual histogram is shown, and this is anno-
tated with the histogram mode and total particle
concentration. To reveal the variation across the mea-
surements, these data are plotted as individual points,
and the average of these measurements is also shown.
This reveals a mode of 9591.94 nm for the averaged
histogram, which sits within the expected range of size
discrimination of the instrument, and compares with
other NanoSight-based observations (9).
In contrast, Fig. 1B reveals analysis of sucrose-cushion-
purified exosomes, from a mesothelioma cell line, or from
the LNCAP cell line (Fig. 1C) performed in an identical
manner. However, this more complex sample reveals
greater variation in the histogram mode compared to
the 100 nm standard beads, and this justifies our choice to
run multiple measurements of each sample. The variation
seen in particle counts is also shown. We have previously
documented the molecular phenotype and structure of
exosomes isolated using the sucrose cushion approach, by
western blotting, electron microscopy and other methods
(8,10,11) revealing these as quality preparations according
to generally accepted criteria.
All particle counting data that follow in this manu-
script were performed in this manner.
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Protein contamination and ratio measurements
We hypothesise that vesicle preparations that are pure
exhibit a relatively high ratio of particles to protein and
thus introducing contaminating protein to the samples
should have a negative effect on the ratio. To empirically
test this, we took a typical sucrose-cushion purified exo-
some preparation, from the LNCAP cell line, and added
elevating concentrations of exogenous BSA. We took care
to filter this BSA through a 20 nm filter and confirmed this
was particle-free using the NanoSight system (not shown).
At each dose of BSA, a protein assay was performed, and
nanoparticles counted as described. The data show that as
protein concentration escalates (Fig. 2A circles), this has
little impact on nanoparticle counts (Fig. 2A squares).
Plotting the ratio of particles per mg of protein (Fig. 2B),
demonstrates falling ratios correlate with samples of
decreasing purity, with a 50% decrease in ratio approxi-
mately equating to an increase in non-vesicular protein of
approximately 4050%, in this assay.
Ratio of particle to protein as a means of comparing
sample purity
Cell-conditioned media was collected from various cul-
tured cell lines, maintained either in the usual 2D 75 cm2
Fig. 1. Measuring beads or extracellular vesicles under flow conditions by nanoparticle tracking. (A) Standard 100 nm beads were
diluted (1 in 1,000) in particle-free water, and measured six times using the NanoSight nanoparticle tracking system. Data from each
repeat measurement is shown, revealing the overall size distribution (histograms) and mode (nm) and particle counts (p/ml). To evaluate
reproducibility of the measurements, the counts (blue squares) and mode (red circles) for each measurement is shown. An average
histogram was plotted from the data, and the mode and particle concentration is calculated (9SD). (B, C) As examples of biological
vesicles, similar analyses using sucrose cushion isolated exosomes secreted from a mesothelioma cell line (B) or the prostate cancer cell
line, LNCAP, (C) showing each measurement and the variation across the six measurements.
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flasks (Fig. 3, pink circles) or in Integra bioreactor flasks
(Fig. 3, purple and red circles). For both cell culture
systems, ratios were calculated for un-purified condi-
tioned media, or following pelleting or pellet and wash
purification methods. For the Integra bioreactor-derived
media, we also conducted our usual sucrose cushion
protocol (Fig. 3, red circles). Cultures from 2D 75 cm2
flasks gave a ratio of approximately 1107 particles per
mg protein (P/mg), and this was elevated 60-fold by
pelleting and a further 4.6-fold after a PBS wash. Media
from Integra bioreactors has higher concentrations of
exosomes, but a comparable amount of non-vesicular
material from FBS, hence these ratios were higher at
3.7108 P/mg, and pelleting and washing elevated the
ratio to around 21010 P/mg. Using the sucrose cushion
method with this starting material, however, gave super-
ior ratios approaching 3.41010 P/mg. For completeness,
we also examined serum-free RPMI, and solutions of
10% FBS in RPMI, using FBS that had apparently
been depleted of exosomes as described in the methods.
In the virtual absence of particles, the ratio for RPMI was
negligible, but there remained detectable particles within
the 10% FBS/RPMI (ratio of 1106 P/mg), defining this
as the background level of non-cell-derived particles in
our culture-derived samples.
Analyses using fresh urine or serum revealed similar
findings, with elevating ratios following pelleting and
washing. However, using these protocols, it was clear
that the ratios achievable using such complex source
material remain vastly inferior to that of cell culture
sources. These data in totum are summarised in Fig. 3A
(logarithmic scale), and also presented in linear scale
plots for culture and biofluid samples separately (Fig. 3B
and C), highlighting more clearly the impact of pellet and
wash steps.
From the current study it would appear that ratios
31010 P/mg equate to high vesicular purity, ratios of
2109 to 21010 P/mg represent low purity, and any
ratios below 1.5109 P/mg are unpure.
Discussion
Here, we demonstrate a simple approach for assessing
purity of single-source intra-laboratory vesicle prepa-
rations, which may also be beneficial across diverse
biomarker, functional and future clinical studies.
The method clearly discriminates pure vesicle prepara-
tions from those replete with contaminating protein;
proposing a ratio of 31010 particles per mg of protein,
or greater as high purity. Preparations with lower ratios,
around three times lower (11010 P/mg), can be achieved
readily by simple pellet and wash protocols. These are
naturally inferior purifications containing significantly
higher levels of contaminating proteins. From the data
shown, a decrease in ratio by 11010 P/mg can indicate
an increase in contaminating proteins by 40% or more.
This is an important consideration when selecting proto-
cols for vesicular purification, which may have subse-
quent effects on analytical interpretation.
By performing these simple experiments, it was sur-
prising how ineffective the wash step was at removing
protein contaminants, providing as little as a 2-fold
increase in ratio compared to the crude pellet. Whilst
there is a consistent loss in total protein following
ultracentrifugation based washing, there is also a loss in
particle counts, due to incomplete recovery of available
material. Hence, washing has only a small impact on
elevating the ratio. Some of the proteins co-pelleted with
Fig. 2. Particle to protein ratio diminishes with contaminating protein. (A) Extracellular vesicles were purified from prostate cancer
cell line (LNCAP) using the sucrose cushion method, and were intentionally contaminated with a solution of bovine serum albumin
that was pre-filtered through a 20 nm filter, and confirmed particle free (not shown). The graph plots the protein concentration (mg/ml,
left axis) and particle concentration (particles/ml, right axis) against the proportion of non-exosomal (contaminating) protein
(% contamination). (B) The ratio of particles to protein for each sample is shown.
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vesicles at the first centrifugation remain present during
the wash step, and may be simply co-purified with vesicles
during the second step. If this is so, no amount of
centrifugation-based washing will be effective in elevating
the ratio of particles to protein. Approaches such as
capturing vesicles based on their flotation characteristics,
whilst more involved, reward by greater elimination of
non-vesicular proteins. In the current study, purification
by the sucrose-cushion method resulted in a ratio of
3.31010 P/mg. This was the highest ratio achieved in the
study, suggesting that this was also the purest vesicular
preparation.
Applying the ratio method to freshly collected bio-
logical fluids demonstrates the difficulties in reaching
comparable purity as achievable with cultured cells. This,
of course, is to be expected given the larger proteome of
such source materials. However, these analyses raise
major concerns about the purity of vesicles currently
used in many studies. Using the pellet and wash protocol
the final ratio achievable when dealing with biological
fluids can be as low as 9.7108 P/mg. This is approxi-
mately 34-fold lower than the maximum purity that we
were able to achieve using the sucrose-cushion method.
From the spike in experiments, ratios below 2.5109
P/mg were evident when samples were 75% non-
vesicular. Hence, we suggest that pellet and wash proto-
cols for biological samples, achieving ratios of B2 109,
lead to very poor purity samples.
Some alternative methods such as sucrose or Opti-
PrepTM gradient centrifugation, dialysis, ultrafiltration or
column chromatography may assist in elevating purity,
above that achievable by the pellet and wash protocols,
and potentially above that of the sucrose cushion
approach. However, complex purification strategies like
these are very time consuming and are unsuited to
medium/high throughput analyses in relation to clinical
trials (11) or biomarker exploration. Robust affinity
capture based approaches are needed, but our method
for purity assessment would likely be affected if this
involves the addition of proteins such as antibodies.
In the analyses of biofluids, we were initially surprised
to find that the ratio achieved with serum specimens
was higher than that of urinary specimens. Given the very
high level of protein in serum compared to urine, we had
expected serum ratios to be strongly negatively impacted.
However, this apparent discrepancy was due to the
absolute concentration of particles in unpurified urine
being very low, approximately 800-fold lower than that in
serum. This is consistent with several studies requiring
significant volumes of urine in order to generate useful
quantities of exosomes (11,12), and accounts therefore
for the low ratios seen in urine.
It is important to mention some caveats regarding the
presented approach. Foremost is that the nanoparticle
tracking approach cannot discriminate vesicles from
non-vesicular particulate material; and here we have
made the assumption that all detected particles are
vesicles. This assumption may be unfair, as there may
be protein aggregates, and large crystals of salts and other
components present giving us an overestimation of the
true number of vesicles present. We anticipate that as
this technology platform evolves, particularly in relation
to its capacity to measure fluorescent particles, future
approaches will be able to discriminate vesicles from
Fig. 3. Use of particle to protein ratio to quantify vesicle purity.
(A) We compared the ratio of particles/protein across various
sample types, and purification methods. This includes specimens
from standard 2D plastic-adherent cultures including un-
purified particles (MCF7 n3, PC3 n2, DU145 n2) vs.
simple pellet (MCF7 n1, PC3 n1, DU145 n1) vs. pellet
and wash (MCF7 n1, PC3 n1, DU145 n1) methods.
These are compared to un-purified particles (PC3 n1, DU145
n2, HT1376 n1) vs. simple pellet (PC3 n1, DU145 n1,
HT1376 n1, LNCAP n1, #15 n1) vs. pellet and wash
(PC3 n1, DU145 n1, HT1376 n1, LNCAP n1, #15
n1) specimens obtained from Integra bioreactor culture
systems, and biological specimens such as fresh serum (n3)
and urine samples (n3). A sucrose cushion method was used
with Integra bioreactor culture supernatants (PC3 n1, DU145
n2, HT1376 n1, LNCAP n1, #15 n1). The ratio
measurement for RPMI and cell-free RPMI containing 10%
FBS is also shown for comparison. (B/C) The same data are
presented as linear plots, to better highlight the difference in
ratio due to pellet and pellet and wash methods. From the
collective data, ratios approaching 31010 are highlighted as
high purity, with those B108 are arbitrarily considered unpure.
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aggregated material, and aid in the refinement of our
proposed method.
The other main caveat is that the method assumes that
each vesicle has a comparable and stable quantity of
protein. This aspect is again unlikely to be strictly true,
as disease states may alter the protein content of vesicles
somewhat (2). The ability of vesicles to passively interact
with, and bind to various proteins in biological systems is
currently underexplored.
Nevertheless, and bearing these issues in mind, the
proposed method presents a useful and quantitative
approach for establishing the purity of vesicle prepara-
tions, and highlights the likely need for additional
purification strategies with respect to biological fluids
that are required to improve vesicle-based biomarker and
other studies.
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